Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques

Current Hematologic Malignancy Reports

Volumn 9, Issue 4, 2014, Pages 368-378

  Biran, Noa ^a   Ely, Scott ^b   Chari, Ajai ^c  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Minimal residual disease; Multiparameter flow cytometry; Multiple myeloma; Next generation sequencing; Polymerase chain reaction

Indexed keywords

BORTEZOMIB; MELPHALAN; PREDNISONE; THALIDOMIDE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD ANALYSIS; CANCER RECURRENCE; CIRCULATING TUMOR CELL; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ASSOCIATION; FLOW CYTOMETRY; HUMAN; IMMUNOGLOBULIN GENE; IMMUNOPHENOTYPING; LIGHT CHAIN; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NEXT GENERATION SEQUENCING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; REVIEW; SENSITIVITY ANALYSIS; URINALYSIS; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NEOPLASM, RESIDUAL; PROCEDURES;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; TRANSPLANTATION, AUTOLOGOUS;

EID: 84916239808     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-014-0237-y     Document Type: Review

References (72)

1. Cavo M et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol: Off J Am Soc Clin Oncol. 2007;25(17):2434–41.
2. Alvares CL et al. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol. 2005;129(5):607–14.
3. Barlogie B et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93(1):55–65.
4. Child JA et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–83.
5. Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679–86.
6. Attal M et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–91.
7. McCarthy PL et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–81.
8. Mateos MV et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934–41.
9. Kumar S et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375–82.
10. Ladetto, M., et al., Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia, 2013
11. Cavo M et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood. 2000;96(1):355–7.
12. Corradini P et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102(5):1927–9.
13. Fenk R et al. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica. 2004;89(5):557–66.
14. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54.
15. Klein B et al. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863–72.
16. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(15):2612–24.
17. Hoering A et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood. 2009;114(7):1299–305.
18. Kim JS et al. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2009;15(4):463–70.
19. Desikan R et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95(12):4008–10.
20. Attal M et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New England J Med. 1996;335(2):91–7.
21. Niesvizky R et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008;143(1):46–53.
22. Attal M et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–502.
23. van de Velde HJ et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92(10):1399–406.
24. Gay F et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025–31.
25. Haessler J et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res: Off J Am Assoc Cancer Res. 2007;13(23):7073–9.
26. Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000;21(3):167–89.
27. Durie BG et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol: Off J Am Soc Clin Oncol. 2004;22(10):1857–63.
28. Kapoor P et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(36):4529–35.
29. Singhal S et al. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood. 2009;114(1):38–9.
30. Ludwig H et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia. 2013;27(1):213–9.
31. Tovar N et al. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2012;18(7):1076–9.
32. Rawstron AC et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(20):2540–7.
33. Paiva B et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687–91.
34. Morgan GJ et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7–15.
35. Paiva B et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(12):1627–33.
36. Leung-Hagesteijn C et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24(3):289–304.
37. Martinez-Lopez J et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results GEM/PETHEMA Stud British J Haematol. 2013;163(5):581–9.
38. Galimberti S et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res. 2005;29(8):961–6.
39. Davies FE et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001;112(3):814–9.
40. Sarasquete ME et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365–72.
41. Davies FE et al. Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol. 2002;15(1):197–222.
42. Lioznov M et al. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques. Bone Marrow Transplant. 2008;41(10):913–6.
43. Mason KD, Juneja S. Go with the flow for monitoring response in myeloma with minimal residual disease. Leuk Lymphoma. 2008;49(2):177–8.
44. Bakkus MH et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol. 2004;126(5):665–74.
45. Putkonen M et al. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol. 2010;85(5):416–23.
46. Martinelli G et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol: Off J Am Soc Clin Oncol. 2000;18(11):2273–81.
47. Corradini P et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol: Off J Am Soc Clin Oncol. 1999;17(1):208–15.
48. Martinelli G et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica. 2000;85(9):930–4.
49. Cremer FW et al. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant. 2000;26(8):851–8.
50. Lemoli RM et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood. 2000;95(7):2234–9.
51. Martinez-Lopez J et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–9.
52. Polzer B, Klein CA. Metastasis awakening: the challenges of targeting minimal residual cancer. Nat Med. 2013;19(3):274–5.
53. Yu M et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012;487(7408):510–3.
54. Bianchi G et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27(3):680–5.
55. Kumar S et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol. 2005;23(24):5668–74.
56. Nowakowski GS et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276–9.
57. Peceliunas V et al. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma. 2012;53(4):641–7.
58. Paiva B et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591–8.
59. Vij R et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2014;14(2):131–139 e1.
60. Bartel TB et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068–76.
61. Zamagni E et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.
62. Walker R et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol: Off J Am Soc Clin Oncol. 2007;25(9):1121–8.
63. Waheed S et al. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica. 2013;98(1):71–8.
64. Cooke F et al. Use of quantitative ASO-PCR to predict relapse in multiple myeloma. Br J Haematol. 1999;105(1):317–9.
65. Ding C, Cantor CR. A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS. Proc Natl Acad Sci U S A. 2003;100(6):3059–64.
66. Radich JP. How I monitor residual disease in chronic myeloid leukemia. Blood. 2009;114(16):3376–81.
67. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol/Oncol Clin North Am. 1999;13(6):1259–72.
68. Snozek CL et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22(10):1933–7.
69. Dispenzieri A et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood. 2008;111(10):4908–15.
70. Novella E et al. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma. Haematologica. 2002;87(11):1157–64.
71. Puig N et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. Comp Anal Flow Cytometry Leuk. 2014;28(2):391–7.
72. Walker RC et al. Imaging of multiple myeloma and related plasma cell dyscrasias. J Nucl Med. 2012;53(7):1091–101.